A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer

British Journal of Cancer

Volumn 77, Issue 11, 1998, Pages 1937-1943

  Ando, M ^a   Watanabe, T ^a   Sasaki, Y ^b   Ying, D F ^c   Omuro, Y ^d   Katsumata, N ^a   Narabayashi, M ^a   Tokue, Y ^e   Fujii, H ^b   Igarashi, T ^b   Wakita, H ^b   Ohtsu, T ^b   Itoh, K ^b   Adachi, I ^a   Taguchi, T ^f  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e TOHOKU UNIVERSITY   (Japan)

^f Japan Soc for Cancer Chemotherapy   (Japan)

Author keywords

5 Fluorouracil; Docetaxel; Metastatic breast cancer; Phase I trial

Indexed keywords

DOCETAXEL; FLUOROURACIL; POLYSORBATE 80;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; EDEMA; ELECTROLYTE DISTURBANCE; FATIGUE; FEMALE; FEVER; HUMAN; HYPOALBUMINEMIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; THROMBOCYTOPENIA; VASCULITIS; VOMITING;

EID: 17544396057     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.321     Document Type: Article

References (25)

1. Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H and Taguchi T (1996) A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73: 210-216
2. Ansfield FJ, Ramizes G, Mackman S, Bryan GT and Curreri AR (1969) A 10-year study of 5-fluorouracil in disseminated breast cancer with clinical results and survival times. Cancer Res 29: 1062-1066
3. Bissery MC, Vrignard P, Bayssas M and Lavelle F (1993) Taxotere synergistic combination with cyclophosphamide, etoposide and 5-fluorouracil in mouse tumor models (abstract). Proc Am Assoc Cancer Res 34: 299
4. Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Bail NL and Kane SB (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523-527
5. Cameron DA, Gabra H and Leonard RCF (1994) Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 70: 120-124
6. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA and Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314-322
7. DeVita VT, Hellman S and Rosenberg SA (1993) Cancer (Principles & Practice of Oncology), 4th edn. Lippincott: Philadelphia. pp. 1315-1322
8. Extra JM, Rousseau F, Bruno R, Clavel M, Bail NL and Marty M (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037-1042
9. Gregory WM, Smith P, Richards MA, Twelves CJ, Knight RK and Rubens RD (1993) Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 68: 988-995
10. Holford NH and Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16: 143-166
11. Hudis CA, Seidman AD, Crown JPA, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R and Norton L (1996) Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14: 58-65
12. Jabboury K, Holmes FA and Hortobagyi GN (1989) 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64: 793-797
13. Jager W, Czejka MJ, Schuller J, Fogl U, Czejka E and Lackner H (1990) Rapid and simple high-performance liquid chromatographic assay for 5-fluorouracil in plasma for bioavailability studies. J Chromatogr 532: 411-417
14. Japanese Breast Cancer Society (1992) General Rules for Clinical and Pathological Recording of Breast Cancer (in Japanese), 11th edn. pp. 53-61. Kanahara: Japan
15. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignard P and Andre S (1995) Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22 (suppl. 4): 3-16
16. Milano G, Roman P, Khater R, Frenay M, Renee N and Namer M (1988) Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 41: 537-541
17. Ravdin PM, Burris III HA, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E and Bellet RE (1995) Phase II trial of docctaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885
18. Ringel I and Horwitz SB (1991) Studies with RP56976: a semisynthetic analogue of Taxol. J Natl Cancer Inst 83: 288-291
19. Taguchi T, Furue H, Niitani H, Ishitani K, Kanamaru R, Hasegawa K, Ariyoshi H, Noda K, Furuse K, Fukuoka M, Yakushiji M and Kashimura M (1994a) Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug (in Japanese). Jpn J Cancer Chemother 21: 1997-2005
20. Taguchi T, Mori S, Abe R, Hasegawa K, Morishita Y, Tabei T, Sasaki Y, Fujita M, Enomoto K, Hamano K, Tominaga T, Sasaki T, Yamaguchi S, Nishiyama K, Iida F, Kanda K, Takagi H, Masaoka A, Takahashi T, Oka T, Takai S, Ota J, Wada T, Yayoi K, Naito Y, Konishi Y, Sonoo H, Hiraki S, Yamamoto Y, Nakase A, Dohi K, Monden Y and Ogawa M (1994b) Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer (in Japanese). Jpn J Cancer Chemother 21: 2625-2632
21. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, Narabayashi M, Fukutomi T, Kondo H, Shimoyama M and Suemasu K (1993) Toxicity grading criteria of the Japanese Clinical Oncology Group. Jpn J Clin Oncol 23: 250-257
22. Trudeau ME, Eisenhauer E, Lofters W, Norris B, Muldal A, Letendre F, Vandenburg T and Verma S (1993) Phase II study of Taxotere as first line chemotherapy for metastatic breast cancer (MBC). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study. Proc Am Soc Clin Oncol 12 (abstract 59)
23. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU and Hortobagyi GN (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894
24. Vergniol JC, Bruno R, Montay G and Frydman A (1992) Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582: 273-278
25. Yamaoka K, Tanigawara Y and Nakagawa T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobio-Dyn 4: 879-885